Cancer refers to a disease of genes that are caused due to abnormal growth of cells. Through blood and lymph system these abnormal cells further migrate from the original site to other site. Lung cancer is type of cancer that is formed in tissues of the lungs. The rise in awareness regarding cancer is escalating the growth of lung cancer therapeutics market.
Frequently Asked Questions
The market is segmented based on Segmentation, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma, Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others) – Industry Trends and Forecast to 2031
.
The Global Lung Cancer Therapeutics Market size was valued at USD 30.06 USD Billion in 2023.
The Global Lung Cancer Therapeutics Market is projected to grow at a CAGR of 10.41% during the forecast period of 2024 to 2031.
The major players operating in the market include Church & Dwight Co. , GlaxoSmithKline plc., Pfizer , Sun Pharmaceutical Industries , Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO. , F. Hoffmann-La Roche Ltd, Novartis AG, Lily., AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co. , CELGENE CORPORATION, Sanofi, Johnson & Johnson Services , Dr. Reddy’s Laboratories , ALLERGAN, Teva Pharmaceutical Industries , Bristol-Myers Squibb Company-.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
